Trevena, Inc. (TRVN) Highlights Phase 2b-BLAST AHF Trial For TRV027 At The European Society Of Cardiology Heart Failure 2014 Meeting
5/19/2014 6:55:04 AM
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that it presented the trial design rationale for its ongoing Phase 2b BLAST-AHF Study of TRV027 in acute heart failure (AHF) at the European Society of Cardiology Heart Failure (ESC-HF) 2014 Meeting, which is taking place May 17 – 20, 2014 in Athens, Greece.
Help employers find you! Check out all the jobs and post your resume.
comments powered by